*New* Update to Zacks Report on Access Pharma
Friday, August 20, 2010
Zacks issues Update on Access Pharma Report
"Grand Zeng of Zacks Research issued an update yesterday on their "Outperform" rating on Access Pharmaceuticals (OTCBB: ACCP) with a six month price target of $8.00. ACCP is trading today at $1.95.
Zacks Equity Research combines quantitative models with the insight provided by experienced equity analysts to create superior long-term stock recommendations.
Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining)."